It often coexists with POTS and shares mechanisms like mitochondrial dysfunction, systemic inflammation, and oxidative stress
The third mechanism is systemic anti-inflammatory signaling, which reduces the inflammatory load that would otherwise slow the structural remodeling process in tendons, ligaments, and muscle
Due to the above-mentioned effects of TZD on glycemic, hepatic metabolism, and inflammation, treatment with dual-agonism may reduce or reverse liver damage (lobular inflammation, hepatic steatosis, liver cell damage, and fibrosis) and metabolic dysfunction (35, 41)
It is widely studied for its regenerative and healing properties
E.Campbell-ThompsonM.GurloT.DawsonD
According to FDA labeling, a gradual dose-escalation protocol allows patients to adjust over time, starting at 0.25 mg and increasing to a maintenance dose of 2.4 mg